Top

Journal of Cancer Research and Clinical Oncology

Published in:

Open Access 01-05-2012 | Original Article

Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer

Authors: Ilhan Gecit, Mehmet Aslan, Mustafa Gunes, Necip Pirincci, Ramazan Esen, Halit Demir, Kadir Ceylan

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2012

Abstract

Objectives

Prolidase is a member of the matrix metalloproteinase family. It plays a major role in collagen turnover, matrix remodeling and cell growth. Nitric oxide (NO) regulates many processes such as collagen synthesis and matrix remodeling. Thus, NO may augment angiogenesis, tumor invasion, and metastasis. The aim of this study was to investigate total antioxidant status (TAS), malondialdehyde (MDA) and NO levels in patients with bladder cancer and to determine their relationship with prolidase activity.

Design and methods

Thirty-five patients with bladder cancer and 32 controls were enrolled. Serum TAS, MDA, prolidase activity and NO levels were determined.

Results

Serum prolidase activity, NO levels and MDA levels were significantly higher in bladder cancer than controls (all, P < 0.05), while TAS levels were significantly lower (P < 0.05).

Conclusions

Our results show that increased prolidase seems to be associated with increased NO levels and oxidative stress along with decreased antioxidant levels in bladder cancer.

Arioz DT, Camuzcuoglu H, Toy H, Kurt S, Celik H, Aksoy N (2009) Serum prolidase activity and oxidative status in patients with stage I endometrial cancer. Int J Gynecol Cancer 19:1244–1247PubMedCrossRef

Batcioglu K, Mehmet N, Ozturk IC et al (2006) Lipid peroxidation and antioxidant status in stomach cancer. Cancer Invest 24:18–21PubMedCrossRef

Beevi SS, Rasheed MH, Geetha A (2007) Evidence of oxidative and nitrosative stress in patients with cervical squamous cell carcinoma. Clin Chim Acta 375:119–132PubMedCrossRef

Bukan N, Sözen S, Coskun U et al (2003) Serum interleukin-18 and nitric oxide activity in bladder carcinoma. Eur Cytokine Netw 14:163–167PubMed

Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Aksoy N (2009) Assessment of preoperative serum prolidase activity in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 147(1):97–100PubMedCrossRef

Cechowska-Pasko M, Pakła J, Wojtukiewicz MZ (2006) Enhanced prolidase activity and decreased collagen content in breast cancer tissue. Int J Exp Pathol 87:289–296PubMedCrossRef

Chinard FP (1952) Photometric estimation of proline and ornithine. J Biol Chem 199:91–95PubMed

Cui S, Reichner JS, Mateo RB, Albina JE (1994) Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or independent mechanisms. Cancer Res 54:2462–2467PubMed

Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2:613–618

Eijan AM, Davel K, Rueda H et al (1998) Differential nitric oxide release and sensitivity to injury in different murine mammarytumor cell lines. Int J Mol Med 2:625–630PubMed

Eijan AM, Piccardo I, Riveros MD et al (2002) Nitric oxide in patients with transitional bladder cancer. J Surg Oncol 81:203–208PubMedCrossRef

Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation more stable ABTS radical cation. Clin Biochem 37:277–285PubMedCrossRef

Gonenc A, Ozkan Y, Torun M, Simsek B (2001) Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J Clin Pharm Ther 26:141–144PubMedCrossRef

Guszczyn T, Sobolewski K (2004) Deregulation of collagen metabolism in human stomach cancer. Pathobiology 71:308–313PubMedCrossRef

Jackson SH, Dennis AN, Greenberg MC (1975) Iminodipeptiduria: a genetic defect in recycling collagen; a method for determining prolidase in erythrocytes. Can Med Ass J 113(759):762–763

Kaczmarek P, Buczyński A, Niemirowicz J et al (2001) Lipids peroxidation in platelets in patients with bladder cancer treated with Mycobacterium suspension. Pol Merkur Lekarski 11:484–486PubMed

Kaplan EP, Richier JC, Howard PS, Ewalt DH, Lin VK (1997) Type III collagen messenger RNA is modulated in non-compliant human bladder tissue. J Urol 157:2366–2369PubMedCrossRef

Karna E, Surazynski A, Palka J (2000) Collagen metabolism disturbances are accompanied by an increase in prolidase activity in lung carcinoma planoepitheliale. Int J Exp Pathol 81:341–347PubMedCrossRef

Kleiner DE, Stetler-Stevenson WG (1999) Matrix metalloproteinases and metastasis. Cancer Chemother Pharmac 43:42–51CrossRef

Knowles RG, Moncada S (1994) Nitric oxide synthase in mammals. Biochem J 198:249–258

Koshland DE Jr (1993) Molecule of the year. Science 262:1953PubMedCrossRef

Liu G, Nakayama K, Awata S et al (2007) Prolidase isoenzymes in the rat: their organ distribution, developmental change and specific inhibitors. Pediatr Res 62:54–59PubMedCrossRef

Macvicar AD (2000) Bladder cancer staging. BJU Int 86:111–122PubMedCrossRef

Marnett LJ (2000) Oxyradicals and DNA damage. Carcinogenesis 21:361–370PubMedCrossRef

Mates JM, Perez-Gomez C, de Castro IN (1999) Antioxidant enzymes and human diseases. Clin Biochem 32:595–603PubMedCrossRef

Mei JM, Borchert GL, Donald SP, Phang JM (2002) Matrix metalloproteinase (s) mediate (s) NO-induced dissociation of beta-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex. Carcinogenesis 23:2119–2122PubMedCrossRef

Myara I, Charpentier C, Lemonnier A (1982) Optimal conditions for prolidase assay by proline colorimetric determination: application to imminodipeptiduria. Clin Chim Acta 125:193–205PubMedCrossRef

Myara I, Charpentier C, Lemonnier A (1984) Prolidase and prolidase deficiency. Life Sci 34:1985–1998PubMedCrossRef

Nishikawa M (2008) Reactive oxygen species in tumor metastasis. Cancer Lett 266:53–59PubMedCrossRef

O’Byrne KJ, Dalgleish AG (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85:473–483PubMedCrossRef

Ozmen H, Erulas FA, Karatas F et al (2006) Comparison of the concentration of trace metals (Ni, Zn, Co, Cu, and Se), Fe, vitamins A, C, and E, and lipid peroxidation in patients with prostate cancer. Clin Chem Lab Med 44:175–179PubMedCrossRef

Palka J, Surazynski A, Karna E et al (2002) Prolidase activity disregulation in chronic pancreatitis and pancreatic cancer. Hepatogastroenterology 49:1699–1703PubMed

Sharma A, Rajjapa M, Saxena A et al (2007) Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation. Br J Biomed Sci 64:23–27PubMed

Surazynski A, Liu Y, Miltyk W, Phang JM (2005) Nitric oxide regulates prolidase activity by serine/threonine phosphorylation. J Cell Biochem 96(5):1086–1094PubMedCrossRef

Surazynski A, Donald SP, Cooper SK et al (2008a) Extracellular matrix and HIF-1 signaling: the role of prolidase. Int J Cancer 122:1435–1440PubMedCrossRef

Surazynski A, Miltyk W, Palka J, Phang JM (2008b) Prolidase-dependent regulation of collagen biosynthesis. Amino Acids 35:731–738PubMedCrossRef

Tas F, Hansel H, Belce A et al (2005) Oxidative stress in breast cancer. Med Oncol 22:11–15PubMedCrossRef

Templar J, Kon SP, Milligan TP, Newman DJ, Raftery MJ (1999) Increased plasma malondialdehyde levels in glomerular disease as determined by a fully validated HPLC method. Nephrol Dial Transplant 14:946–951PubMedCrossRef

Tracey WR, Tse J, Carter G (1995) Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther 272:1011–1015PubMed

Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr (2004) Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 9:53–61PubMedCrossRef

Wolf H, Haeckel C, Roessner A (2000) Inducible nitric oxide synthase expression in human urinary bladder cancer. Virchows Arch 437:662–666PubMedCrossRef

Wynder EL, Goldsmith R (1977) The epidemiology of bladder cancer: a second look. Cancer 40:1246–1268PubMedCrossRef

Yalcin O, Karatas F, Erulas FA et al (2004) The levels of glutathione peroxidase, vitamins A, E, C, and lipid peroxidation in patients with urothelial carcinoma of the bladder. BJU Int 93:863–866PubMedCrossRef

Yoshimura R, Wada S, Matsuyama M, Hase T, Goto T, Tanaka T, Kuratsukuri K, Tsuchida K, Nakatani T (2004) Urinary extracellular matrix measurement as a reliable and cost effective diagnostic tool for bladder tumors. Int J Mol Med 13(1):127–131PubMed

Yoshioka T, Kawada K, Shimada T et al (1979) Lipid peroxidation in maternal and cord blood and protective mechanisms against activated oxygen toxicity in the blood. Am J Obster Gynecol 135:372–376

Zeegers MP, Kellen E, Buntinx F, van den Brandt PA (2004) The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol 21:392–401PubMedCrossRef

Title: Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer
Authors: Ilhan Gecit
Mehmet Aslan
Mustafa Gunes
Necip Pirincci
Ramazan Esen
Halit Demir
Kadir Ceylan
Publication date: 01-05-2012
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 5/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-011-1136-4

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer

Abstract

Objectives

Design and methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Objectives

Design and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2012

Methotrexate-mediated inhibition of RAD51 expression and homologous recombination in cancer cells

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines

Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment

Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo

The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

A novel xenograft model with intrinsic vascularisation for growing undifferentiated pleomorphic sarcoma NOS in mice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page